Total turnover on the Shanghai and Shenzhen exchanges on Sept. 30 was CNY1,438.02 bln, up CNY28.82 bln from the prior session. Shanghai turnover CNY679.40 bln (previous CNY661.70 bln), volume 415 mln lots; Shenzhen turnover CNY758.62 bln (previous CNY747.49 bln), volume 495 mln lots. Largest single-stock turnover: Zhongji Xuchuang CNY12.85 bln, followed by Xinyisheng CNY9.60 bln, Hengtong Optic‑Electric CNY8.95 bln, Cambricon CNY8.69 bln and GigaDevice CNY8.65 bln.

Citi raised Hengrui Medicine (01276.HK) H‑share PT to HK$120 (from HK$119) and A‑share PT to 111 yuan (from 109 yuan), increases of 0.8% and 1.8%, and kept the stock as a top pick. Citi flagged a licensing deal with Novo Nordisk (NVO.N) for HRS‑1596 that could be worth up to $2.6 billion, with an expected $300 million upfront in Q4 2026 and revenue to be recognized in Q4 2026 or Q1 2027; the bank noted the structure allows Hengrui to monetize ex‑China via Novo’s global metabolic platform while retaining full China commercialization rights.

A股房地產板塊持續拉昇，陸家嘴漲停，中天服務此前漲停，濱江集團、深物業A、萬科A、深深房A紛紛衝高。